

# UC Davis

## UC Davis Previously Published Works

### Title

Aging, Alzheimer's, and APOE genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50.

### Permalink

<https://escholarship.org/uc/item/1jt345m8>

### Authors

Aboud, Orwa  
Parcon, Paul A  
DeWall, K Mark  
et al.

### Publication Date

2015

### DOI

10.3389/fncel.2015.00103

Peer reviewed

# Aging, Alzheimer's, and *APOE* genotype influence the expression and neuronal distribution patterns of microtubule motor protein dynactin-P50

Orwa Aboud<sup>1†</sup>, Paul A. Parcon<sup>1†</sup>, K. Mark DeWall<sup>1,2†</sup>, Ling Liu<sup>1</sup>, Robert E. Mrak<sup>3</sup> and W. Sue T. Griffin<sup>1,4\*</sup>

<sup>1</sup> Donald W. Reynolds Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA,

<sup>2</sup> Department of Biology, Brigham Young University, Idaho, Rexburg, ID, USA, <sup>3</sup> Department of Pathology, University of Toledo Health Sciences Campus, Toledo, OH, USA, <sup>4</sup> Geriatric Research, Education, Clinical Center, Central Arkansas HealthCare System, Little Rock, AR, USA

## OPEN ACCESS

### Edited by:

Lawrence Rajendran,  
University Zurich, Switzerland

### Reviewed by:

Daniel Kaganovich,  
Hebrew University of Jerusalem, Israel  
Carlo Di Cristo,  
University of Sannio, Italy

### \*Correspondence:

W. Sue T. Griffin,  
Donald W. Reynolds Department of  
Geriatrics, University of Arkansas for  
Medical Sciences, 629 Jack Stephens  
Drive, Little Rock, AR 72205, USA  
griffinsuet@uams.edu

<sup>†</sup>These authors have contributed  
equally to this work.

**Received:** 10 December 2014

**Accepted:** 09 March 2015

**Published:** 25 March 2015

### Citation:

Aboud O, Parcon PA, DeWall KM, Liu  
L, Mrak RE and Griffin WST (2015)  
Aging, Alzheimer's, and *APOE*  
genotype influence the expression and  
neuronal distribution patterns of  
microtubule motor protein  
dynactin-P50.  
*Front. Cell. Neurosci.* 9:103.  
doi: 10.3389/fncel.2015.00103

Reports from neural cell cultures and experimental animal studies provide evidence of age- and disease-related changes in retrograde transport of spent or misfolded proteins destined for degradation or recycling. However, few studies address these issues in human brain from those who either age without dementia and overt neuropathology, or succumb to Alzheimer's; especially as such propensity may be influenced by *APOE* genotype. We studied the expression and distribution of the dynein subunit dynactin-P50, the  $\beta$  amyloid precursor protein ( $\beta$ APP), and hyperphosphorylated tau (P-tau) in tissues and tissue sections of brains from non-demented, neuropathology-free patients and from Alzheimer patients, with either *APOE*  $\epsilon$ 3,3 or *APOE*  $\epsilon$ 4,4. We found that advanced age in patients without dementia or neuropathological change was associated with coordinated increases in dynactin-P50 and  $\beta$ APP in neurons in pyramidal layers of the hippocampus. In contrast, in Alzheimer's,  $\beta$ APP and dynactin were significantly reduced. Furthermore, the dynactin-P50 and  $\beta$ APP that was present was located primarily in dystrophic neurites in A $\beta$  plaques. Tissues from Alzheimer patients with *APOE*  $\epsilon$ 3,3 had less P-tau, more  $\beta$ APP, dynactin-P50, and synaptophysin than did tissues from Alzheimer patients carrying *APOE*  $\epsilon$ 4,4. It is logical to conclude, then, that as neurons age successfully, there is coordination between retrograde delivery and maintenance and repair, as well as between retrograde delivery and degradation and/or recycling of spent proteins. The buildup of proteins slated for repair, synaptic viability, transport, and re-cycling in neuron soma and dystrophic neurites suggest a loss of this coordination in Alzheimer neurons. Inheritance of *APOE*  $\epsilon$ 3,3 rather than *APOE*  $\epsilon$ 4,4, is associated with neuronal resilience, suggestive of better repair capabilities, more synapses, more efficient transport, and less hyperphosphorylation of tau. We conclude that even in disease the  $\epsilon$ 3 allele is neuroprotective.

**Keywords:** aging, Alzheimer, *APOE* genotype,  $\beta$ APP, dynactin-P50, motor proteins, P-tau, synaptophysin

## Introduction

Fast-axonal transport is an essential part of normal neuronal function (Paschal and Vallee, 1987; Brady, 1991), and transport failures manifest as a dying-back of axons from the synapse to the neuronal soma, a phenomena that occurs prior to the neuronal loss characteristic of Alzheimer's disease (AD) (Kanaan et al., 2013). The retrograde transport complex dynein is a large multi-subunit complex, which attaches to its cargo by the dynactin-P50 subunit (Chen et al., 2014). Dynein-mediated transport is speculated to be mostly regulated by the dynactin complex (Stokin and Goldstein, 2006). The active dynein complex is important in alignment of microtubules and is, at least partially, responsible for the growth of microtubules into the growth cone of axons (Ahmad et al., 2006). These functions suggest that dynein is needed for neuronal survival, especially for the survival of those neurons with long axons that function to connect CNS neuronal somas with distant targets in the periphery (Ebneith et al., 1998; Heerssen et al., 2004). Further, dynein-mediated axonal transport depends on interactions between neurotrophic factors, their receptors, and the dynein complex. For example, decreased brain-derived neurotrophic factor (BDNF) is associated with decreased retrograde transport (Heerssen et al., 2004).

Among the endosomes transported by dynein, many contain A $\beta$  or  $\beta$ APP; the latter being expressed in response to neuronal stress imposed by neural injury (Rosen et al., 1989; Kimura et al., 2009). Elevated expression of  $\beta$ APP is a neuronal response believed to be neuroprotective (Masliah et al., 1997) based on findings in mice deficient in  $\beta$ APP; such mice display deficits in long term potentiation and memory (Dawson et al., 1999). Normal transport of excess  $\beta$ APP and A $\beta$  to the soma for degradation is necessary to terminate reactions, which over time may facilitate A $\beta$  deposition. For example, as a result of breakdown in endosome transport, A $\beta$  vesicles in the cell build up, causing further neuronal stress, further increases in  $\beta$ APP production, and inhibition of A $\beta$  reuptake and processing, leading to A $\beta$  deposition (Kimura et al., 2009). Such deposition has been noted in neurons adjacent to A $\beta$  plaques, and is characterized by a failure to mount appropriate neuronal acute phase responses such as elevation of  $\beta$ APP (Barger et al., 2008).

The genesis and stability of microtubules is dependent on appropriately phosphorylated tau, a principal microtubule-associated protein that is necessary for genesis and stability of the microtubule tracks that are used in intracellular transport (Yoon et al., 2008) and in maintenance of the unipolarity of the axon, which is important for dynein and kinesin motor functions (Ebneith et al., 1998). Tau is normally distributed along the axon in a decreasing gradient, with low tau concentration near the cell body, and higher concentrations near the axonal ending, for appropriate attachment of motor proteins (Dixit et al., 2008). In the absence of regulation, there is neuritic beading, axonal swelling, and bulbous neurites, which is presumably due to steric hindrance or microtubule dysfunction in the areas of the swelling (Tan et al., 2007; Kimura et al., 2009). With either broken tracks or an obstacle in its path, tau begins to build up in the soma, which may result from, or may lead to, its hyperphosphorylation and ultimately formation of neurofibrillary tangles

(NFTs) in cell bodies and apical dendrites, in distal dendrites as neuropil threads, as well as in the enlarged dystrophic neurites in A $\beta$  plaques (Gotz et al., 2006).

Several studies dating back to as early as 1967 suggest that microtubule-dependent transport is impaired in Alzheimer's disease (Suzuki and Terry, 1967) (for review see Stokin and Goldstein, 2006). The correlation between neurofibrillary tangles and dementia severity (Gotz et al., 2006) may be related to abnormal phosphorylation of tau and resultant changes in axonal transport of hyperphosphorylated tau and  $\beta$ APP, as well as other cellular entities (Greenberg and Kosik, 1995). For instance, the presence in axons and neurites of abnormal swellings containing neurofibrillary tangles, phagocytic elements, and mitochondria (Pilling et al., 2006; Tan et al., 2007) suggests that motor protein dysfunction and/or microtubule loss (Cash et al., 2003) contribute to these anomalies. This is of considerable interest as failures in endosomal functions that are dependent on retrograde transport by the dynein system leave the neuron unable to rid itself of unwanted or misfolded proteins, and spent organelles. It is also important to note that in both Alzheimer's and Down's syndrome, endosomal changes are among the earliest pathological anomalies (Cataldo et al., 1996, 2003), suggesting that failures in this system are particularly powerful as they occur early and are persistent, with middle and end stage accumulation of unwanted proteins in synaptic areas.

The role of *APOE* genotype in risk for development of Alzheimer's is well known (Saunders et al., 1993; Strittmatter et al., 1993; LaDu et al., 1994; Weisgraber and Mahley, 1996), and the potential additive effect of having *APOE*  $\epsilon$ 4 allele(s) on the risk for developing Alzheimer's in risk-conferring neurological conditions such as in head trauma (Nicoll et al., 1995; Reinvang et al., 2013) and in temporal lobe epilepsy (Mackenzie and Miller, 1994; Gouras et al., 1997; Aboud et al., 2012, 2013) has been reported. *APOE* genotype has also been shown to impact age-associated cognitive status (Vemuri et al., 2010, 2014) and is associated with vocabulary loss with age (Baxter et al., 2003), especially in the context of more limited education and less intellectual stimulation (Bunce et al., 2014). Only recently has it been suggested that inheritance of specific *APOE* genotypes may be more related to the ability of one genotype to confer neuronal resilience rather than neurodegeneration; that is, allelic combinations without  $\epsilon$ 4 are more resilient than combinations with  $\epsilon$ 4 (Caesar and Gandy, 2012).

To assess whether age and/or Alzheimer's and *APOE* genotype are related to changes in neuronal and tissue levels of the neuronal acute phase response protein  $\beta$ APP, the retrograde microtubule motor protein dynactin-P50, accumulation of hyperphosphorylated tau in NFTs, or synaptic loss (as denoted by a reduction in the synaptic marker synaptophysin), human brain tissue samples and tissue sections from brains of cognitively intact patients at different ages (age-matched control, or AMC), and from Alzheimer patients were immunoreacted with antibodies that specifically recognize dynactin-P50,  $\beta$ APP, synaptophysin, and hyperphosphorylation sites on the tau in neurofibrillary tangles. Dynactin-P50 expression in neurons in both hippocampal dentate gyrus and pyramidal neuron areas increased with normal aging, while such expression in Alzheimer

patients was markedly less. Similarly, the expression of  $\beta$ APP was elevated with aging, but not with Alzheimer's. Disease-associated decreases in neuronal  $\beta$ APP and dynactin-P50 expression were accompanied by an accumulation of  $\beta$ APP, dynactin-P50, and neurofibrillary tangles in neuron somas and dystrophic neuritic compartments, especially in neuritic plaques. The relative levels of  $\beta$ APP, dynactin-P50, and synaptophysin were higher in tissue from APOE  $\epsilon$ 3, $\epsilon$ 3 carriers than in APOE  $\epsilon$ 4, $\epsilon$ 4 carriers, while the levels of hyperphosphorylated tau were higher in APOE  $\epsilon$ 4, $\epsilon$ 4 than APOE  $\epsilon$ 3, $\epsilon$ 3 carriers.

## Materials and Methods

### Patients and Specimens

Hippocampal tissues from 23 brains obtained at autopsy from 11 neurologically normal individuals (AMC, ages 16–81 years, all APOE  $\epsilon$ 3, $\epsilon$ 3) and 12 Alzheimer patients (ages 68–90 years; 4 APOE  $\epsilon$ 3, $\epsilon$ 4 and 8 APOE  $\epsilon$ 3, $\epsilon$ 3) were used for immunohistochemical analysis of cellular expression of dynactin-P50,  $\beta$ APP, and hyperphosphorylated tau. To assess the potential role of APOE  $\epsilon$ 3, $\epsilon$ 3 vs. APOE  $\epsilon$ 4, $\epsilon$ 4 in dynactin-P50 and dynein/cargo interactions, hippocampal tissue from 11 Alzheimer patients (5 APOE  $\epsilon$ 3, $\epsilon$ 3 and 6 APOE  $\epsilon$ 4, $\epsilon$ 4) and 4 APOE  $\epsilon$ 3, $\epsilon$ 3 neurologically normal controls was evaluated with respect to the relative tissue levels of dynactin-p50, hyperphosphorylated tau, and synaptophysin. All tissues were neuropathologically evaluated and the diagnoses of AD or AMC were made according to National Institute of Aging-Reagan guidelines<sup>1</sup>.

### Fluorescent Immunohistochemistry

As described in a previous study (Barger et al., 2008), paraffin was removed in xylene from 7  $\mu$ m paraffin-embedded tissue sections and rehydrated in graduated ethanol solutions to deionized water. Sections were incubated in 3% H<sub>2</sub>O<sub>2</sub> in 97% methanol for 30 min at room temperature and washed 3 times with PBS. For  $\beta$ APP, dynactin P-50, and AT8 labeling, tissue sections were pretreated by boiling in 1 mmol/L of EDTA (pH 8.0) for 10 min at medium power in a microwave oven. After 3 rinses in PBS, all sections were blocked in 80% Dulbecco's Modified Eagle's Medium [DMEM], 19% fetal calf serum, 1% bovine serum albumin for 1 h at room temperature. After PBS rinses, sections were incubated with primary antibody solutions overnight at room temperature: mouse anti-dynactin P-50 (1:1000) (BD Bioscience, San Jose, CA), mouse anti- $\beta$ APP (1:100) (Zymed, Grand Island, NY), and mouse anti-hyperphosphorylated tau (AT8) (1:2000) (Thermo Scientific, Pittsburgh, PA). After PBS rinses, a pre-diluted horse anti-mouse immunoglobulin G conjugated to peroxidase (Vector, Burlingame, CA) was further diluted 1:5 for detection of dynactin P-50, hyperphosphorylated tau (AT8), and  $\beta$ APP primary antibodies. Development of the immunofluorescent signal was achieved by signal amplification with Alexa Fluor 350, 488, and 594 tyramide (Molecular Probes, Eugene, OR), using

the manufacturer's recommended conditions. Before the addition of the second or third primary antibody in double and triple labeling experiments, slides were rinsed in PBS, incubated in 0.01 N HCl for 10 min at room temperature to inactivate peroxidase, rinsed again in PBS, and subjected to antigen-specific pretreatments as necessary. Previous to secondary antibody application, lipofuscin staining was blocked by pretreatment with Sudan Black B dissolved in 80% ethanol (Sigma, St. Louis, MO). Tissue sections were counterstained with 100 ng/ml 4',6 diamino-2-phenylindole dihydrochloride (DAPI, Invitrogen, Grand Island, NY) for 5 min at room temperature to visualize nuclei. To prevent fading of immunofluorescence, the tissue sections were mounted with Vectashield mounting medium (Vector, Burlingame, CA).

In this study, we use "expression" to mean fluorescence intensity. The fluorescence intensity of  $\beta$ APP, dynactin, and p-tau in immunoreacted tissues were examined according to standardized laboratory practices using a Nikon Eclipse E600 microscope with a Y-FL epifluorescence attachment (Barger et al., 2008; Aboud et al., 2012, 2013). A CoolSNAP ES digital camera (Roper Scientific, Ottobrunn, Germany) was used to capture images from the hippocampus, and the parahippocampal gyrus at 20 $\times$  or 40 $\times$  magnification under identical conditions (exposure times). Thresholding and total fluorescence intensity calculations were derived from gray-scale images (Figure 1)—captured using NIS-Elements BR3 (Nikon.com) and MetaVue 6.2r2 software (Molecular Devices, Sunnyvale, CA) at a minimum threshold range of 300 and 600 for dynactin P-50 and  $\beta$ APP—in neurons, i.e., cells with nuclear diameters greater than 8  $\mu$ m and in neurites, i.e., plaque-associated, non-nucleated immunoreactive entities (Figure 1).


In brief, quantification protocols were as follows: initial image samples were taken for each patient to determine optimal exposure times, such that all signal was clearly detected and no pixels were saturated. Once exposure time was determined, images from all slides were taken at the same exposure time, with multiple images taken in areas of interest in each sample. NIS-Elements software denotes pixel saturation, and fields containing such saturation due to blood vessels or other artifacts were excluded from data collection and calculation. Intensity calculations are averaged for each individual, with the average intensity considered as a single data point for statistical analysis.

### Duolink Proximity Ligation Assay

Duolink PLA kits were purchased from Sigma, and were used according to manufacturer's protocols. In brief, slides were treated similar to immunofluorescent protocols above, with the replacement of fluorescent antibodies with oligonucleotide-conjugated secondary antibodies (termed PLUS and MINUS) that are complementary and form a circular nucleotide sequence if the two secondary antibodies are within 40 nm distance from each other. Slides are treated with a ligase following the secondary antibodies, and then a fluorescent signal is produced by rolling circle elongation from the circular DNA strand formed from the PLUS and MINUS antibodies. Duolink was performed with the dynactin-P50 and AT8 primary antibodies listed above.

<sup>1</sup>1997. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol. Aging 18, S1–S2.

## Grayscale images and overlays for fluorescence intensity calculations in neuritic plaques



8 x 8 crops from 20X images.

**FIGURE 1 | Examples of immunofluorescent images used in neuritic plaque color overlays and for grayscale quantification.** Separate channel images were taken and overlaid, and colocalization

was assessed based on color combinations, e.g., Red + Green = Yellow. Red represents hyperphosphorylated tau (AT8) and green represents dynactin-P50 (DynP50).

### Western Immunoblot Analysis

Proteins were extracted from tissue with a lysis buffer comprised of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate and 0.1% SDS; lysates were quantified using a Micro BCA assay reagent kit (Pierce, Rockford IL) as described previously (Li et al., 1998). Aliquots (100 μg each) were loaded onto 10% SDS-polyacrylamide gels, subjected to electrophoresis at 70V for 20 min and 90V for 1.5 h, and transferred to nitrocellulose membranes. Membrane blots were blocked in I-Block Buffer (Applied Biosystem Inc., Bedford, MA) for 45 min, then incubated overnight separately at 4°C with primary antibodies to: P-tau (AT8, 1:1000); dynactin-P50 (1:1000); synaptophysin 1:1000; or actin (1:5000), incubated for 1 h at room temperature with alkaline phosphatase-conjugated secondary antibody, and developed using the Western-Light™ Chemiluminescent Detection System (Applied Biosystem Inc., Bedford MA). Autoradiographs were digitized and analyzed using NIH ImageJ software, version 1.60. Results are reported as steady-state levels, relative to actin.

### Statistical Analysis

Group differences were determined by Wilcoxon-Mann-Whitney Rank Sum Test for significance, with two tails and  $\alpha = 0.05$ . Results are expressed as mean  $\pm$  SEM.

## Results

### $\beta$ APP and Dynactin-P50 Expression Increased with Age


Due to the elongated morphology of neurons and their unique functions, precise and timely delivery of specific proteins and

organelles by motor proteins must be tightly maintained. In particular, retrograde transport of spent proteins or damaged organelles is very important and is predicted to change with age, as oxidative and inflammatory stresses accumulate with the wear and tear of time. To investigate this prediction, we ask a simple question: Are there changes in the expression of the regulatory cargo attachment protein dynactin-p50 and its cargo  $\beta$ APP with increasing age in the absence of disease? Dynactin-P50 fluorescent intensity (expression) was noticeably elevated with increasing age, from teenage to the eighth decade, in pyramidal neurons in hippocampal tissue sections from neurologically and neuropathologically normal individuals (Figures 2A,B). This age-related increase in dynactin-P50 expression was accompanied by an increase in  $\beta$ APP expression in neuronal somas and neuronal processes (Figures 2A,C), suggesting that in response to the normal wear and tear of time,  $\beta$ APP and dynactin expression are increased for membrane repair and transport of cellular entities.

### $\beta$ APP and Dynactin-P50 Expression is Diminished in Alzheimer Hippocampus

In order to assess the effect of AD on the amount of  $\beta$ APP and dynactin-p50 in the neurons of those with Alzheimer's disease, separate from the effect of normal aging, we selected cases with Alzheimer's disease, and compared them to control individuals that matched them closely in age (AMCs were within 1 year of their AD counterparts, with the total age range for both groups between 69 and 80). We found that there was a dramatic decrease in dynactin-P50 expression in analogous neurons in Alzheimer patients (Figures 3A,B). This decrease is suggestive of the idea that in AD, neurons are unable to transport proteins to the soma for degradation and recycling, perhaps accounting, at least in






part, for the deleterious downstream consequences of a build-up of misfolded proteins and potentially-neurotoxic aggregates. The decrease in dynactin-P50 expression in neurons in tissue from Alzheimer patients, compared to that in tissue from age-matched neurologically normal individuals, was accompanied by a similarly marked decrease in neuronal betaAPP (Figures 4A,B) and in betaAPP mRNA, as we previously reported (Barger et al., 2008).

### Dynactin, betaAPP, and Neurofibrillary Tangles are Colocalized and Distributed throughout Neurons in Alzheimer's

In neurologically normal individuals, the increased expression of dynactin-P50 and betaAPP associated with advancing age was apparent in the soma and in the axon hillock of both dentate and pyramidal neurons (Figure 5, 1st row). In contrast, in Alzheimer tissue from analogous regions of hippocampus, the expression of dynactin-P50 and betaAPP was dramatically reduced in dentate and pyramidal neurons (Figure 5, 2nd and 3rd row). Moreover, in dynactin-P50 and betaAPP-immunoreactive neurons that also

contained neurofibrillary tangles, there was an apparent preferential redistribution of all three antigens from neuronal somas to neuritic bulbous terminals (Figure 5, neuron soma, white arrows; anuclear neurites, yellow arrows). Large tangle-bearing pyramidal neurons were also noted to contain both betaAPP and dynactin-P50. In fact, P-tau immunoreactive tangles, betaAPP, and dynactin-P50 appear to be trapped in both soma and neurites (Figure 5, red arrows), which may be due, at least in part, to disruption of the entire (anterograde and retrograde) microtubule motor system, as might be inferred from previous studies demonstrating that endosomal transport and processing are disrupted in Down's syndrome and in Alzheimer's disease (Cataldo et al., 1996). To determine proximity of P-tau and dynactin-p50, we probed tissue with the Duolink Proximity Ligation Assay (PLA). This assay produces a fluorescent signal if two immunogens are within 40 nm distance by using complementary DNA strands on antibody probes with subsequent ligation and detection. In this way, we showed that dynactin-P50 and P-tau are indeed located within 40 nm of each other in neuritic plaques in AD (Figure 5B), strongly suggesting aggregation.



### Hyperphosphorylated Tau is Increased, and Dynactin-P50 and Synaptophysin are Decreased in *APOE* $\epsilon 4,4$ Alzheimer Patients Compared to $\epsilon 3,3$

Marked differences in fluorescence intensity were noted in AD patients depending on their *APOE* genotype. Those with  $\epsilon 3,3$  genotypes had overall higher dynactin-P50 levels and lower P-Tau levels compared to their  $\epsilon 4,4$  counterparts (Figures 6A,B, representative images, Figure 6C, fluorescence quantification). This was confirmed in Western blot: relative to actin steady-state levels, overall, the expression of hyperphosphorylated tau is higher in Alzheimer patients with *APOE*  $\epsilon 4,4$  than in patients with *APOE*  $\epsilon 3,3$ , while dynactin and synaptophysin were lower (Figures 6D,E). As synaptophysin is commonly used as a marker for healthy functional synapses, this implies a connection between *APOE* genotype, retrograde transport, and synaptic integrity. Interestingly, in comparing the right-most lanes in the Alzheimer  $\epsilon 3,3$  and  $\epsilon 4,4$  western blot (Figure 6E, gray boxes), the hyperphosphorylated tau, synaptophysin, and dynactin-P50 levels are almost identical, perhaps explained by risk factors other than *APOE* genotype.


### Discussion

It is clear that successful brain aging, that is, aging free of dementia and of Alzheimer neuropathology at autopsy, is possible as many people live to old age without dementia (Evans et al., 1989; Paganini-Hill et al., 2015). This suggests that in successful aging, the brain meets the challenges of stresses that come with aging by bringing into play mechanisms that are necessary to maintain the status quo in a neuron. Such maintenance requires appropriate

regulation (i.e., synthesis and activation) of proteins involved in the following: maintenance of membranes (e.g.,  $\beta$ APP); microtubule stability (e.g., tau); anterograde transport of proteins to where they are needed (via kinesin); retrograde transport of spent proteins and organelles (via dynein); and proper degradation and processing of spent proteins (ubiquitination for proteostasis). Numerous cell culture and experimental animal research studies have shown age-related changes in neuronal functions, many of which involve molecular mechanisms of neuronal transport systems. Our aim here was to define and characterize retrograde transport protein levels that accompany successful aging, and how those that aged successfully differed from those with Alzheimer's disease. We note here that in successful aging, there is a coordinated increase in dynactin and  $\beta$ APP with advancing age. In contrast, many of the changes we discuss in successful aging may not occur in those with Alzheimer's disease, such that less  $\beta$ APP and dynactin are produced in those with AD compared to their age-matched counterparts, and that the dynactin and APP which is produced is trapped in aggregates with hyperphosphorylated tau. Further, these deleterious effects are exacerbated by inheritance of *APOE*  $\epsilon 4,4$  alleles in comparison to inheritance of *APOE*  $\epsilon 3,3$ . Our data is consistent with the idea that Alzheimer's disease constitutes a failure of neurons to sustain the levels of  $\beta$ APP and dynactin-P50 necessary for the increased demands imposed by aging, especially in combination with other risk factors such as inheritance of *APOE*  $\epsilon 4$ .

### Normal Aging

We focused on  $\beta$ APP because it is the acute phase response protein in neurons (Barger et al., 2008) and is of particular importance in Alzheimer pathogenesis; and on dynein, in particular dynactin-P50, the cargo-binding protein of dynein, because



**FIGURE 4 |  $\beta$ APP levels are reduced in Alzheimer's (AD), and dynactin-P50 (DynP50) and  $\beta$ APP localization is disrupted.** Dynactin-P50 (green) and  $\beta$ APP (red) were detected by immunofluorescence in tissue sections from hippocampus. **(A)** Total APP intensity is decreased in AD cases. Blue represents DAPI staining of cellular DNA. Images were

digitized at 40 $\times$  magnification. Scale bar = 10  $\mu$ m. **(B)** Overall  $\beta$ APP fluorescence intensity is diminished in AD compared to neurologically normal controls (AMC). Significance determined by Wilcoxon-Mann-Whitney Rank Sum Test, with \*denoting  $p \leq 0.05$ . Data reported as group mean with error bars denoting SEM.

$\beta$ APP is a prominent cargo for retrograde transport (Gunawardena et al., 2013). As we are interested in age-related effects, we restricted our cohort to patients without dementia and without neuropathology at autopsy. In our sample, we show that  $\beta$ APP expression increases with age, and that this increase is accompanied by an increase in dynactin-P50. This is consistent with the idea that aging stress induces increased  $\beta$ APP production, and that this increased  $\beta$ APP necessitates a concomitant increase in transport proteins, as illustrated with dynactin-P50 in our study. Other studies have also pointed to differential expression of this system depending on age. Age-related increases in specific isoforms and fragments of  $\beta$ APP (133 and 19 kDa, respectively) have been reported to occur with advancing age (Nordstedt et al., 1991), while decreases in microtubule density, the “tracks” upon which dynein complexes travel, are also occurring in an age-related manner (Cash et al., 2003). In 2007, Kimura et al. reported yet another effect, this time in aged monkeys: with increased age, the interaction between the dynein intermediate chain and dynactin was reduced, possibly due to phosphorylation state, and leading to decreased retrograde transport efficiency (Kimura et al., 2007). All of these effects may be responsible for possibly compensatory increases in dynactin we report here. We feel that it should be stressed here that individuals used in this study, even of advanced age, did not have disease, and the implication therein is that age alone is not sufficient to lead to neuropathology, as long as compensatory mechanisms function correctly.

**$\beta$ APP and Dynactin in Alzheimer's Disease**


The story is different in individuals with neurodegenerative disease. Axonal transport disturbances are important factors in several neurological disorders, including Parkinson's disease (Chu

et al., 2012) and amyotrophic lateral sclerosis (Ikenaka et al., 2012). Similar disturbances in axonal transport have been suggested to occur in Alzheimer's disease, based on the dystrophic appearance of axons and their bulbous neurites and dendrites in Alzheimer brain (Stokin and Goldstein, 2006). These characteristic defects in AD are suggestive of defects in axonal transport and have been widely reported on by many groups (Heerssen et al., 2004; Ahmad et al., 2006; Kimura et al., 2009). Our finding of dramatic reductions in neuronal dynein expression in Alzheimer brain, relative to that in neurologically normal controls of similar age (AMC), provides necessary support for the early suggestion by Terry (1998) that motor protein abnormalities are principal factors in synaptic pathology. Although this Alzheimer-related reduction in dynactin-P50 that we show relative to that in AMC is unlikely to be the only contributor to neuronal dysfunction, it is likely to be an important component of the endosomal-lysosomal system dysfunction that is related to defects in  $\beta$ APP processing in AD (i.e., autophagy) (Cataldo et al., 1996), and in Down's (Cataldo et al., 2000). It may be the case that such transport protein dysfunction is secondary to primary lysosomal defects: Lee et al. demonstrated that lysosomal dysfunction was sufficient to cause axonal transport deficits of the like seen in Alzheimer's disease (Lee et al., 2011).

**Neurofibrillary Tangles**

The co-localization of dynein and  $\beta$ APP as well as dynein and hyperphosphorylated tau in Alzheimer disease is consistent with the idea that—unlike the state of affairs in aged controls—spent or misfolded proteins, that would otherwise be transported back to the soma for degradation or recycling, are sequestered in aggregates in neurites and in somas. The presence






of the retrograde motor protein dynactin-P50 in these aggregates, together with the fact that less dynactin-P50 is present overall in Alzheimer brain, supports a prominent role for retrograde transport dysfunction in Alzheimer pathogenesis. Moreover, the Alzheimer-related changes in dynein expression and distribution reported here, together with the sequestering of abnormal proteins in somas and terminals may contribute to the synaptic loss in AD that Terry and Katzman suggest is related to decreases in cognition and increased risk for precocious development of AD (Terry and Katzman, 2001).

The early finding of the importance of tau in the genesis and stabilization of microtubules (Black et al., 1986) has implications for our study in that the hyperphosphorylation of tau and subsequent formation of neurofibrillary tangles suggests sequestration of hyperphosphorylated tau in such tangles may decrease the amount of tau available for its normal functions to promote production of microtubule associated proteins for genesis and stability of microtubules (Trojanowski and Lee, 2005). This, along

with the reported decrease in microtubule density with increasing age (Cash et al., 2003), the weakened synthesis of dynein, and the paucity of non-aggregated dynactin-P50 in Alzheimer neuron somas that we show here, suggest that in Alzheimer's, disruption in synthesis of transport proteins necessary for cellular and synaptic maintenance and repair leads to failures in proteostasis, synaptic loss, and neuronal dysfunction and death. While there is still no firmly established relationship between Aβ plaques and the presence and distribution of neurofibrillary tangles within neurons in Alzheimer's (Armstrong et al., 1993), our finding of both βAPP and dynactin-P50 in neurofibrillary tangle-laden bulbous neurites in plaques as well as in plaque-adjacent neuron somas suggests that plaques and plaque proximity may contribute to retrograde transport dysfunction and therefore to the buildup, rather than the degradation, of toxic aggregates such as hyperphosphorylated tau. Indeed, in Alzheimer's disease, increasing plaque complexity (diffuse to diffuse neuritic to dense-core neuritic) is associated with more βAPP-immunoreactive neurites



and more activated astrocytes overexpressing S100B (Mrak et al., 1996), which could further exacerbate neuronal transport deficits, through its promotion of  $\beta$ APP synthesis and neurite outgrowth and its dose-dependent induction of microtubule associated protein 2 (Li et al., 1998).

### ***APOE* genotype**

We present evidence here that *APOE* genotype has a part in the pathogenesis of these transport deficits. Our findings show that the tissue levels of dynactin-P50 and synaptophysin are lower in Alzheimer patients with *APOE* ε4,4 compared to *APOE* ε3,3, while hyperphosphorylated tau is elevated, suggesting that inheritance of ε3,3 confers a measure of neuronal resilience, even in the presence of Alzheimer's disease. Our findings regarding the influence of *APOE* genotype on the steady state levels of the motor protein dynactin-P50 and one of its potential cargoes, hyperphosphorylated tau, suggests that, compared to carriers of *APOE* ε3,3, carriers of *APOE* ε4,4 are at increased risk of excessive aggregation in neuronal soma and dystrophic neurites of spent and misfolded proteins. Therefore, these aggregated proteins are

not available to proteasomes or lysosomes for degradation or re-cycling.

It is important to note that possession of *APOE* ε3,3 genotype alone does not protect against disease-associated risk factors that themselves increase hyperphosphorylated tau. It does appear that as hyperphosphorylated tau increases above some level in carriers of *APOE* ε3,3 with disease, there is *not* a corresponding increase in motor proteins. Moreover, *APOE* ε3,3 carriers who have hyperphosphorylated tau levels similar to carriers of *APOE* ε4,4 also have levels of synaptophysin that are similar to those of ε4,4 carriers. The association between high hyperphosphorylated tau, low dynactin-P50, and synaptic loss, as denoted by low synaptophysin levels noted in one of our ε3,3 cases, suggests that factors other than *APOE* genotype are involved in aggregate formation, and may separately contribute to retrograde transport deficits. It is interesting to note that elevation of IL-1 $\beta$ , the bellwether of Alzheimer's neuroinflammation, increases synthesis of MAPKp38 and production of its active phosphorylated form, viz., the form of MAPKp38 that we found necessary for production of hyperphosphorylated tau and for the reduction of synthesis of

synaptophysin (Li et al., 2003). In view of this, in the many conditions in which IL-1 $\beta$  levels are elevated, it is logical to predict a corresponding increase in production of hyperphosphorylated tau and a decrease in production of synaptophysin, regardless of APOE genotype.

## Conclusion

Age imposes increasing amounts of neural stress, even in a person free of dementia and of neuropathological change. This stress is mitigated in neurons by increasing the levels of the neuronal stress response protein  $\beta$ APP and its retrograde transport protein dynactin-P50, allowing for retrograde transport of  $\beta$ APP, which after use, may need to be re-cycled or degraded. However, in Alzheimer's, a combination of factors, including APOE genotype, disrupts this stress response system beyond its ability to cope, and in this way, initiates and perpetuates a cycle in which A $\beta$  is generated, and tau hyperphosphorylation and aggregation are favored. These proteins may then stick together, and sequester useful proteins such as dynactin-P50 into aggregates, preventing them from performing their function; this deleterious cycle leads to synaptic loss, and eventually cell death. In addition to the risk factors we mention here, namely, APOE genotype, other reports imply other factors can come into play, specifically endosome/lysosome dysfunction (Kimura et al., 2009; Lee et al., 2011), microtubule density reduction (Cash et al., 2003), and decreased dynein/dynactin interaction (Kimura et al., 2007), leading to decreased transport efficiency. This idea points to the possibility of targeting the protein transport system in development of Alzheimer treatments, in addition to its important regulators: inflammation, proteostasis, and stress-response.

Our findings suggest that neurodegenerative events seen in Alzheimer's are related to dysregulation of microtubule-associated motors that carry proteins and other cargo to and

from the neuronal soma, causing an accumulation of dynactin-P50,  $\beta$ APP, and neurofibrillary tangles in the bulbous neurite endings present in the neuritic amyloid plaques diagnostic of Alzheimer's disease. The fact that each of these entities is also present in neuronal somas, especially those adjacent to plaques, suggests that not only retrograde but also anterograde motor systems are impacted in Alzheimer pathogenesis. Our finding that even in disease APOE  $\epsilon$ 3,3 plays an ameliorating role in potential for delivery of spent and misfolded proteins may explain, at least in part, the benefits of inheriting this genotype on risk of development of Alzheimer's. Importantly, our findings make clear the possibility of successful aging characterized by necessary changes in transport measures to meet age-related challenges, such as changes in the expression of cargo entities associated with age-appropriate expression of proteins, organelles, and neurotransmitters.

## Author Contributions

OA, KM, and PP shared equally in the work and in manuscript preparation, LL performed the westerns and their analyses, RM performed the neuropathological evaluations and contributed to preparation of the manuscript, and WG led the project, data interpretation, and manuscript writing.

## Acknowledgments

The authors wish to thank Sue Woodward and Jo Ann Biedermann for technical assistance.

## Support

NIH/NIA AG12411 and the Windgate Foundation.

## References

- Aboud, O., Mrak, R. E., Boop, F., and Griffin, S. T. (2012). Apolipoprotein epsilon3 alleles are associated with indicators of neuronal resilience. *BMC Med.* 10:35. doi: 10.1186/1741-7015-10-35
- Aboud, O., Mrak, R. E., Boop, F. A., and Griffin, W. S. (2013). Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype. *Acta Neuropathol. Commun.* 1:41. doi: 10.1186/2051-5960-1-41
- Ahmad, F. J., He, Y., Myers, K. A., Hasaka, T. P., Francis, F., Black, M. M., et al. (2006). Effects of dynactin disruption and dynein depletion on axonal microtubules. *Traffic* 7, 524–537. doi: 10.1111/j.1600-0854.2006.00403.x
- Armstrong, R. A., Myers, D., and Smith, C. U. (1993). The spatial patterns of plaques and tangles in Alzheimer's disease do not support the 'cascade hypothesis'. *Dementia* 4, 16–20.
- Barger, S. W., DeWall, K. M., Liu, L., Mrak, R. E., and Griffin, W. S. (2008). Relationships between expression of apolipoprotein E and beta-amyloid precursor protein are altered in proximity to Alzheimer beta-amyloid plaques: potential explanations from cell culture studies. *J. Neuropathol. Exp. Neurol.* 67, 773–783. doi: 10.1097/NEN.0b013e318180ec47
- Baxter, L. C., Caselli, R. J., Johnson, S. C., Reiman, E., and Osborne, D. (2003). Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. *Neurobiol. Aging* 24, 947–952. doi: 10.1016/S0197-4580(03)00006-X
- Black, M. M., Aletta, J. M., and Greene, L. A. (1986). Regulation of microtubule composition and stability during nerve growth factor-promoted neurite outgrowth. *J. Cell Biol.* 103, 545–557. doi: 10.1083/jcb.103.2.545
- Brady, S. T. (1991). Molecular motors in the nervous system. *Neuron* 7, 521–533. doi: 10.1016/0896-6273(91)90365-7
- Bunce, D., Bielak, A. A., Anstey, K. J., Cherbuin, N., Batterham, P. J., and Eastaig, S. (2014). APOE genotype and cognitive change in young, middle-aged, and older adults living in the community. *J. Gerontol. A Biol. Sci. Med. Sci.* 69, 379–386. doi: 10.1093/gerona/glt103
- Caesar, I., and Gandy, S. (2012). Evidence that an APOE epsilon4 'double whammy' increases risk for Alzheimer's disease. *BMC Med.* 10:36. doi: 10.1186/1741-7015-10-36
- Cash, A. D., Aliev, G., Siedlak, S. L., Nunomura, A., Fujioka, H., Zhu, X., et al. (2003). Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. *Am. J. Pathol.* 162, 1623–1627. doi: 10.1016/S0002-9440(10)64296-4
- Cataldo, A. M., Hamilton, D. J., Barnett, J. L., Paskevich, P. A., and Nixon, R. A. (1996). Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. *J. Neurosci.* 16, 186–199.
- Cataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., et al. (2003). App gene dosage modulates endosomal abnormalities of



- Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. *J. Neurosci.* 23, 6788–6792.
- Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., and Nixon, R. A. (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. *Am. J. Pathol.* 157, 277–286. doi: 10.1016/S0002-9440(10)64538-5
- Chen, X. J., Xu, H., Cooper, H. M., and Liu, Y. (2014). Cytoplasmic dynein: a key player in neurodegenerative and neurodevelopmental diseases. *Sci. China Life Sci.* 57, 372–377. doi: 10.1007/s11427-014-4639-9
- Chu, Y., Morfini, G. A., Langhamer, L. B., He, Y., Brady, S. T., and Kordower, J. H. (2012). Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. *Brain* 135(Pt 7), 2058–2073. doi: 10.1093/brain/aw133
- Dawson, G. R., Seabrook, G. R., Zheng, H., Smith, D. W., Graham, S., O'Dowd, G., et al. (1999). Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. *Neuroscience* 90, 1–13. doi: 10.1016/S0306-4522(98)00410-2
- Dixit, R., Ross, J. L., Goldman, Y. E., and Holzbaur, E. L. (2008). Differential regulation of dynein and kinesin motor proteins by tau. *Science* 319, 1086–1089. doi: 10.1126/science.1152993
- Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. (1998). Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. *J. Cell Biol.* 143, 777–794. doi: 10.1083/jcb.143.3.777
- Evans, D. A., Funkenstein, H. H., Albert, M. S., Scherr, P. A., Cook, N. R., Chown, M. J., et al. (1989). Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. *JAMA* 262, 2551–2556. doi: 10.1001/jama.1989.03430180093036
- Gotz, J., Ittner, L. M., and Kins, S. (2006). Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? *J. Neurochem.* 98, 993–1006. doi: 10.1111/j.1471-4159.2006.03955.x
- Gouras, G. K., Relkin, N. R., Sweeney, D. G., Mackenzie, I. R., and Gandy, S. (1997). Increased apolipoprotein E epsilon 4 in epilepsy with senile plaques. *Ann. Neurol.* 41, 402–404. doi: 10.1002/ana.410410317
- Greenberg, S. M., and Kosik, K. S. (1995). Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons. *Neurobiol. Aging* 16, 403–407. discussion: 7–8. doi: 10.1016/0197-4580(94)00172-W
- Gunawardena, S., Yang, G., and Goldstein, L. S. (2013). Presenilin controls kinesin-1 and dynein function during APP-vesicle transport *in vivo*. *Hum. Mol. Genet.* 22, 3828–3843. doi: 10.1093/hmg/ddt237
- Heerssen, H. M., Pazyra, M. F., and Segal, R. A. (2004). Dynein motors transport activated Trks to promote survival of target-dependent neurons. *Nat. Neurosci.* 7, 596–604. doi: 10.1038/nn1242
- Ikenaka, K., Katsuno, M., Kawai, K., Ishigaki, S., Tanaka, F., and Sobue, G. (2012). Disruption of axonal transport in motor neuron diseases. *Int. J. Mol. Sci.* 13, 1225–1238. doi: 10.3390/ijms13011225
- Kanaan, N. M., Pignino, G. F., Brady, S. T., Lazarov, O., Binder, L. I., and Morfini, G. A. (2013). Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. *Exp. Neurol.* 246, 44–53. doi: 10.1016/j.expneurol.2012.06.003
- Kimura, N., Imamura, O., Ono, F., and Terao, K. (2007). Aging attenuates dynein-dynein interaction: down-regulation of dynein causes accumulation of endogenous tau and amyloid precursor protein in human neuroblastoma cells. *J. Neurosci. Res.* 85, 2909–2916. doi: 10.1002/jnr.21408
- Kimura, N., Inoue, M., Okabayashi, S., Ono, F., and Negishi, T. (2009). Dynein dysfunction induces endocytic pathology accompanied by an increase in Rab GTPases: a potential mechanism underlying age-dependent endocytic dysfunction. *J. Biol. Chem.* 284, 31291–31302. doi: 10.1074/jbc.M109.012625
- LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., and Frail, D. E. (1994). Isoform-specific binding of apolipoprotein E to beta-amyloid. *J. Biol. Chem.* 269, 23403–23406.
- Lee, S., Sato, Y., and Nixon, R. A. (2011). Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. *J. Neurosci.* 31, 7817–7830. doi: 10.1523/JNEUROSCI.6412-10.2011
- Li, Y., Liu, L., Barger, S. W., and Griffin, W. S. (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. *J. Neurosci.* 23, 1605–1611.
- Li, Y., Wang, J., Sheng, J. G., Liu, L., Barger, S. W., Jones, R. A., et al. (1998). S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. *J. Neurochem.* 71, 1421–1428. doi: 10.1046/j.1471-4159.1998.71041421.x
- Mackenzie, I. R., and Miller, L. A. (1994). Senile plaques in temporal lobe epilepsy. *Acta Neuropathol. (Berl.)* 87, 504–510. doi: 10.1007/BF00294177
- Masliah, E., Westland, C. E., Rockenstein, E. M., Abraham, C. R., Mallory, M., Veinberg, I., et al. (1997). Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries *in vivo*. *Neuroscience* 78, 135–146. doi: 10.1016/S0306-4522(96)00553-2
- Mrak, R. E., Sheng, J. G., and Griffin, W. S. (1996). Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. *J. Neuropathol. Exp. Neurol.* 55, 273–279. doi: 10.1097/00005072-199603000-00002
- Nicoll, J. A., Roberts, G. W., and Graham, D. I. (1995). Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. *Nat. Med.* 1, 135–137. doi: 10.1038/nm0295-135
- Nordstedt, C., Gandy, S. E., Alafuzoff, I., Caporaso, G. L., Iverfeldt, K., Grebb, J. A., et al. (1991). Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment. *Proc. Natl. Acad. Sci. U.S.A.* 88, 8910–8914. doi: 10.1073/pnas.88.20.8910
- Paganini-Hill, A., Kawas, C. H., and Corrada, M. M. (2015). Lifestyle factors and dementia in the oldest-old: the 90+ study. *Alzheimer Dis. Assoc. Disord.* [Epub ahead of print].
- Paschal, B. M., and Vallee, R. B. (1987). Retrograde transport by the microtubule-associated protein MAP 1C. *Nature* 330, 181–183. doi: 10.1038/330181a0
- Pilling, A. D., Horiuchi, D., Lively, C. M., and Saxton, W. M. (2006). Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in *Drosophila* motor axons. *Mol. Biol. Cell* 17, 2057–2068. doi: 10.1091/mbc.E05-06-0526
- Reinvang, I., Espeseth, T., and Westlye, L. T. (2013). APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. *Neurosci. Biobehav. Rev.* 37, 1322–1335. doi: 10.1016/j.neubiorev.2013.05.006
- Rosen, D. R., Martin-Morris, L., Luo, L. Q., and White, K. (1989). A *Drosophila* gene encoding a protein resembling the human beta-amyloid protein precursor. *Proc. Natl. Acad. Sci. U.S.A.* 86, 2478–2482. doi: 10.1073/pnas.86.7.2478
- Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology* 43, 1467–1472. doi: 10.1212/WNL.43.8.1467
- Stokin, G. B., and Goldstein, L. S. (2006). Axonal transport and Alzheimer's disease. *Annu. Rev. Biochem.* 75, 607–627. doi: 10.1146/annurev.biochem.75.103004.142637
- Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. U.S.A.* 90, 1977–1981. doi: 10.1073/pnas.90.5.1977
- Suzuki, K., and Terry, R. D. (1967). Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. *Acta Neuropathol.* 8, 276–284. doi: 10.1007/BF00688828
- Tan, Z., Sun, X., Hou, F. S., Oh, H. W., Hilgenberg, L. G., Hol, E. M., et al. (2007). Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. *Cell Death Differ.* 14, 1721–1732. doi: 10.1038/sj.cdd.4402180
- Terry, R. D. (1998). The cytoskeleton in Alzheimer disease. *J. Neural Transm. Suppl.* 53, 141–145. doi: 10.1007/978-3-7091-6467-9\_12
- Terry, R. D., and Katzman, R. (2001). Life span and synapses: will there be a primary senile dementia? *Neurobiol. Aging* 22, 347–348. discussion: 53–54. doi: 10.1016/S0197-4580(00)00250-5
- Trojanowski, J. Q., and Lee, V. M. (2005). Pathological tau: a loss of normal function or a gain in toxicity? *Nat. Neurosci.* 8, 1136–1137. doi: 10.1038/nn0905-1136
- Vemuri, P., Lesnick, T. G., Przybelski, S. A., Machulda, M., Knopman, D. S., Mielke, M. M., et al. (2014). Association of lifetime intellectual enrichment with



- cognitive decline in the older population. *JAMA Neurol.* 71, 1017–1024. doi: 10.1001/jamaneurol.2014.963
- Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., et al. (2010). Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. *Ann. Neurol.* 67, 308–316. doi: 10.1002/ana.21953
- Weisgraber, K. H., and Mahley, R. W. (1996). Human apolipoprotein E: the Alzheimer's disease connection. *FASEB J.* 10, 1485–1494.
- Yoon, S. Y., Choi, J. E., Choi, J. M., and Kim, D. H. (2008). Dynein cleavage and microtubule accumulation in okadaic acid-treated neurons. *Neurosci. Lett.* 437, 111–115. doi: 10.1016/j.neulet.2008.03.083

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Aboud, Parcon, DeWall, Liu, Mrak and Griffin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.